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Abstract
Understanding the potential profile of adverse events associated with cancer treatment is essential
in balancing safety vs. benefits. Multiple stakeholders make use of this information towards
decision-making, including patients, clinicians, researchers, regulators, and payors. Currently,
adverse events are reported by clinical research staff, yet evidence suggests that this may
contribute to under-reporting of symptom events. Direct patient reporting via electronic interfaces
offers a promising mechanism to enhance the efficiency and precision of our current approach,
and may complement clinician reports of adverse events. The National Cancer Institute has
contracted to develop and test an item bank and software system for directly eliciting adverse
symptom event information from patients in cancer clinical research, called the Patient-Reported
Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). The
validity, usability, and scalability of the PRO-CTCAE prototype are currently being examined in
academic and community-based settings.
Adverse event reporting in the regulatory context
Limitations of drug safety monitoring in both the preapproval and post-market settings are
widely acknowledged.1 From an informatics perspective, these limitations are related to the
quality of information collected, as well as to processes for efficient collection, aggregation
and analysis of these data, and methods of communication to stakeholders -- including
patients, clinicians, regulators, and payors.2,3
Information about adverse events in oncology is typically derived from prospective clinical
trials conducted in the regulatory setting towards obtaining drug approval, as well as from
post-market studies (or in rare cases, case reports or voluntary reporting via mechanisms like
the U.S. Food and Drug Administration's Adverse Event Reporting System [AERS]). Post-
market studies may be conducted as part of an industry sponsor's post-market regulatory
obligation to the U.S. Food and Drug Administration (FDA), or may be conducted by
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independent investigators and organizations outside of this framework (such as in the U.S.
National Cancer Institute's [NCI's] cooperative groups).
U.S. drug labels include adverse event information which is largely derived from research
conducted by sponsors in the regulatory context, and filtered by sponsors and regulators
based on frequency and severity of these events. It is common for oncology drug labels to
list 50 to 100 individual adverse reactions, which is comparable to labels in other diseases
(Table 1). This number of side effects can be overwhelming to patients trying to determine
what experience they are likely to have with a particular treatment.4 In the U.S., drug labels
are currently being redesigned, in part due to recognition that greater clarity about adverse
reactions is needed.
Adverse event reporting in comparative effectiveness research
In the largely non-regulated space of comparative effectiveness research (CER), there is
even less scrutiny about the precision of adverse event collection and reporting. Despite
Institutional Review Board (IRB) oversight and existing mechanisms for monitoring safety
data in CER studies which involve patients, standards for how adverse event information is
reported both to IRBs and in publications vary widely. Information about product safety
derived from CER studies conducted by independent investigators generally is not
incorporated into drug labels for the products being evaluated. Therefore, patients,
clinicians, and third-party aggregators of clinical information – such as drug information
databases, compendia, or developers of systematic reviews, clinical practice guidelines, and
decision-support tools – are left to pool and weight data about safety from disparate sources.
In the context of CER, in which studies are intended to reflect the balance between risks and
benefits in real-world populations with patients as the key stakeholders, one would expect
even greater attention to be paid to the safety of interventions under evaluation. Moreover,
assessment of the comparative tolerability of products is an essential component of CER,
and depends on the fidelity of safety reporting. The recent U.S. Patient Protection and
Affordable Care Act created an independent organization to identify methodological
standards in CER, including standards for the measurement and reporting of harms, called
the Patient-Centered Outcomes Research Institute (PCORI). An area of focus of PCORI is
standardization of the assessment of safety in CER.
Adverse symptom events
About a third of adverse reactions listed in oncology drugs are symptoms (Table 1).
Capturing symptom data in clinical trials differs from other types of adverse event data (e.g.,
laboratory tests) in that it depends on eliciting subjective information from patients. It is
acknowledged that the current process in oncology clinical trials for eliciting adverse
symptom event information from patients is inadequate.5 Evidence indicates that the validity
of reporting symptom outcomes is eroded when those reports are filtered through clinical
staff.11 Symptoms experienced by patients are often underestimated by clinical staff
members who are responsible for eliciting and reporting this information (both in terms of
frequency of occurrence and severity).6 Staff-based adverse event reporting occurs at clinic
visits and thus symptoms that occur between visits may be missed.
This presents a challenge from the informatics perspective. In order for an adverse symptom
event to be documented in clinical research, the patient must first articulate the problem to a
responsible clinical staff member. The staff member will then document that event,
generally in a medical chart. This documentation may be on paper or electronic, and
generally does not involve use of a standardized valid measurement scale. Subsequently, this
information is abstracted by a different staff member and converted to a standardized
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terminology, such as the Medical Dictionary for Regulatory Affairs (MedDRA), or the NCI
Common Terminology Criteria for Adverse Events (CTCAE). During this process of
information flow, the reported experience of the patient may be modified either due to
interpretation by the clinical staff member (e.g., “Mrs. Jones doesn't look like she's in that
much pain, she says severe, but I suspect it's mild”), or due to the process of mapping the
reported experience to the standardized lexicon (“The medical chart says the patient is
queezy, that probably means nausea in the CTCAE”).
Adverse event reporting and patient-reported outcomes
Recently, standards for collecting information directly from patients in clinical trials have
been consolidated in an FDA Guidance document.7 These standards largely pertain to
patient-reported outcomes (PROs) which are intended to result in a labeling claim in the
regulatory setting (e.g., improved pain in metastatic prostate cancer), but have also been
widely adopted outside of the regulatory setting. The implication of these standards is that
symptom experiences of patients should be reported by patients themselves, in order to
minimize loss or transformation of this information. The patient knows his or her experience
best, and is in the best position to meaningfully report on it, without interpretation or
modification by an observer.8
However, the use of PROs has been largely restricted to collection of data to support the
efficacy of products, rather than their safety. While it is now common in clinical trials for
specific symptoms or health-related quality of life domains to be assessed via patient self-
report questionnaires to support assertions of product efficacy or effectiveness, adverse
symptom events continue to be elicited, filtered, and reported by clinical staff members.
Direct patient reporting of this information has been proposed as an alternative approach
which is more efficient and less prone to data loss, misinterpretation, or transformation.2,5
Patient reporting of symptoms is more reliable and valid than clinician reporting, and is
more highly correlated with measures of functional performance and health status than
clinician reports.9,10,11 Patient reporting better identifies baseline symptoms related to pre-
existing conditions, and patients are willing and able to self-report their own adverse
symptom events – even patients with end-stage disease and poor performance status.,9,12
Adverse event reporting and informatics
Despite acknowledged limitations in the assessment of adverse symptom events, there has
been substantial progress in the standardization of adverse event reporting in general.
MedDRA is a hierarchical lexicon of adverse event terms which was created by an
International Conference on Harmonisation, and is maintained across languages by the
International Federation of Pharmaceutical Manufacturers and Associations. MedDRA is
universally used in clinical trials in the regulatory context. In oncology specifically, the
NCI's CTCAE is the standard item bank used for adverse event reporting. While MedDRA
only includes terms for AEs, the CTCAE includes specific criteria for grading the severities
of AEs. AE terms used in the CTCAE were recently harmonized with MedDRA in its
update to CTCAE version 4. Therefore, almost all cancer clinical trials report adverse events
based on the same criteria, the CTCAE, with mapping of these terms to MedDRA.
In clinical trials sponsored by the NCI, two electronic systems have been used for
centralized reporting of AE's: the Adverse Event Expedited Reporting System (AdEERS)
and Clinical Data Update System (CDUS). Both of these systems require reporting using
CTCAE criteria.
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Integration of adverse event reporting into electronic clinical trial management systems and
electronic medical records is also increasingly common, and in the future will allow for real-
time monitoring of adverse events at the patient and group levels. Finally, efforts are
underway to improve post-market safety surveillance by linking large databases, such as the
FDA's SENTINEL initiative (www.fda.gov/Safety/FDAsSentinelInitiative/
ucm2007250.htm).
The overall goal of these efforts is to standardize terminologies and improve the efficiency
of reporting and aggregating large amounts of adverse event information by harnessing
technology. However, none of them addresses the limitations involved with primary data
collection and documentation of patients’ symptoms. Therefore, the information being
standardized and aggregated is by its nature insufficient.
The National Cancer Institute's PRO-CTCAE Initiative
Based on recognition of limitations of the current approach to adverse symptom event
documentation in cancer trials, in 2008, the NCI contracted for the development of a patient-
reported outcomes version of the CTCAE, called the PRO-CTCAE, and an accompanying
software platform.13 The scope of this contract, which was awarded to Memorial Sloan-
Kettering Cancer Center, includes creating patient questionnaires that assess adverse
symptom events; developing an electronic platform for administering these questionnaires to
patients via web or telephone (i.e., interactive voice response system [IVRS]) and for
reporting the data to clinicians and investigators; testing the measurement properties of
PRO-CTCAE questions; and evaluating the feasibility of integrating this approach into
multi-center clinical trials.
To date, 124 items representing 78 discrete symptoms in the CTCAE have been developed
in English and refined via a cognitive interviewing study in a diverse national sample.14 A
multi-site validation study is ongoing in more than 1000 patients,15 as well as a national
usability testing evaluation of the software.16 The items have been translated into Spanish
and are undergoing linguistic validation; translations into additional languages are underway
via Material Transfer Agreements established between the NCI and interested investigators.
Moreover, feasibility studies are commencing within multi-center clinical trials in the NCI
cooperative groups.
Functionality of the PRO-CTCAE software platform includes the ability for investigators to
build and schedule electronic questionnaires for patient self-reporting (Figure 1). Skip
patterns to minimize respondent burden are integrated, and the software provides
mechanism for patients to report additional symptoms beyond the PRO-CTCAE items, from
an existing menu derived from MedDRA, or as free text. Automated alerts are sent to
clinical staff for missed reports or symptoms that exceed pre-specified thresholds. Reports
can show patient-level or study-level information in standardized graphical formats. The
system was designed to be compatible with related software systems supported by the NCI
for data capture and adverse event reporting in clinical research.
Conclusion
Electronic patient reporting may improve the quality and comprehensiveness of oncology
drug safety information collected in clinical research. The model of reporting that will
evolve in the future remains to be determined, but conceivably an approach in which directly
reported patient information informs mandatory staff adverse event reporting could emerge.
How this information should be used to optimize decision-making and reporting of data in
early-phase and phase III trials are areas of active research sponsored by the NCI.
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Beyond the clinical trial setting, patient-reported indices of safety and tolerability may play
a role in longitudinal registries and safety surveillance systems. Moreover, there is
increasing interest to integrate this information into routine cancer care.17 Ultimately, the
goal of this work is to develop information systems that allow the patient perspective to be
better represented in clinical research, and to develop therapies and care processes which are
tailored to patient's preferences and will optimize therapeutic response.
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Screenshots of the PRO-CTCAE Web platform, version 1.0. A, Form builder for research
staff to create a PRO-CTCAE form. B, Web interface for patients to complete questions in a
form (also available via an automated telephone system).
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Table 1
Adverse Events (AEs) Listed in U.S. Drug Labels
Indication # of U.S. Drug Labels Average # of AEs per Label Proportion of AEs That Are Symptoms
Asthma 35 54 54%
Breast cancer 32 83 38%
Gastroesophageal reflux disease 18 121 47%
Hyperlipidemia 28 86 46%
Osteoarthritis 39 94 43%
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